Open Access

Clinical features of patients with pancreatic ductal adenocarcinoma with a history of other primary malignancies: A retrospective analysis

  • Authors:
    • Hironori Hayashi
    • Koji Amaya
    • Tomokazu Tokoro
    • Kosuke Mori
    • Shunsuke Takenaka
    • Yuya Sugimoto
    • Yuto Kitano
    • Toru Kurata
    • Shunsuke Kawai
    • Atsushi Hirose
    • Tomoya Tsukada
    • Masahide Kaji
    • Koichi Shimizu
    • Kiichi Maeda
  • View Affiliations

  • Published online on: June 29, 2021     https://doi.org/10.3892/mco.2021.2335
  • Article Number: 173
  • Copyright: © Hayashi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Patients with pancreatic ductal adenocarcinoma (PDAC) that have a history of other primary malignancies are not well documented. The current study therefore aimed to evaluate the clinicopathological characteristics of patients with PDAC with or without a history of other primary malignancies. A total of 102 patients with surgically treated PDAC that presented with or without a history of other primary malignancies were retrospectively analyzed. A total of 25 patients (24.5%) had a history of other primary malignancies (age, with history of other primary malignancy vs. without, 74.2 vs. 68.9 years; P=0.005) and the reason for consultation (P<0.001) differed significantly between the groups with a history of other primary malignancies [HoM(+)] and without a history of other primary malignancies [HoM(‑)]. Incidental indications during malignancy follow‑up was the most common reason for the diagnosis of PDAC in the HoM(+) group. Conversely, there were no significant differences in the resectability (P=0.645), complete resection rate (P=0.774) and final stage (P=0.474) between the two groups. Disease‑free survival was also not significantly different between the two groups (P=0.184). However, overall survival was significantly poorer in the HoM(+) group compared with the HoM(‑) group (P=0.003). A history of other primary malignancies was also an independent predictor of poor overall survival (hazard ratio, 2.416; 95% confidence interval, 1.324‑4.406; P=0.004). In conclusion, patients with PDAC and a history of other primary malignancies had significantly poorer overall survival than their counterparts, despite no differences in disease‑free survival.
View Figures
View References

Related Articles

Journal Cover

September-2021
Volume 15 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Hayashi H, Amaya K, Tokoro T, Mori K, Takenaka S, Sugimoto Y, Kitano Y, Kurata T, Kawai S, Hirose A, Hirose A, et al: Clinical features of patients with pancreatic ductal adenocarcinoma with a history of other primary malignancies: A retrospective analysis. Mol Clin Oncol 15: 173, 2021.
APA
Hayashi, H., Amaya, K., Tokoro, T., Mori, K., Takenaka, S., Sugimoto, Y. ... Maeda, K. (2021). Clinical features of patients with pancreatic ductal adenocarcinoma with a history of other primary malignancies: A retrospective analysis. Molecular and Clinical Oncology, 15, 173. https://doi.org/10.3892/mco.2021.2335
MLA
Hayashi, H., Amaya, K., Tokoro, T., Mori, K., Takenaka, S., Sugimoto, Y., Kitano, Y., Kurata, T., Kawai, S., Hirose, A., Tsukada, T., Kaji, M., Shimizu, K., Maeda, K."Clinical features of patients with pancreatic ductal adenocarcinoma with a history of other primary malignancies: A retrospective analysis". Molecular and Clinical Oncology 15.3 (2021): 173.
Chicago
Hayashi, H., Amaya, K., Tokoro, T., Mori, K., Takenaka, S., Sugimoto, Y., Kitano, Y., Kurata, T., Kawai, S., Hirose, A., Tsukada, T., Kaji, M., Shimizu, K., Maeda, K."Clinical features of patients with pancreatic ductal adenocarcinoma with a history of other primary malignancies: A retrospective analysis". Molecular and Clinical Oncology 15, no. 3 (2021): 173. https://doi.org/10.3892/mco.2021.2335